Which statin should be used together with colchicine? Clinical experience in three patients with nephrotic syndrome due to AA type amyloidosis

Rheumatology International

Volumn 28, Issue 3, 2008, Pages 289-291

  Sahin, Garip ^a   Korkmaz, Cengiz ^a,b   Yalcin, Ahmet Uǧur ^a  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

^b NONE   (Turkey)

Author keywords

Amyloidosis; Colchicine; Familial Mediterranean fever; Neuromyopathy; Statins

Indexed keywords

ATORVASTATIN; COLCHICINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ADULT; ARTICLE; CASE REPORT; DRUG DOSE INCREASE; DRUG SAFETY; DRUG WITHDRAWAL; FAMILIAL MEDITERRANEAN FEVER; HUMAN; HYPERLIPIDEMIA; KIDNEY AMYLOIDOSIS; LOW DRUG DOSE; MALE; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEINURIA; SENSORIMOTOR NEUROPATHY; TREATMENT OUTCOME;

ADULT; AMYLOIDOSIS; COLCHICINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FAMILIAL MEDITERRANEAN FEVER; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NEPHROTIC SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 37249063052     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-007-0435-1     Document Type: Article

References (11)

1. Ensari C, Ensari A, Tumer N, Ertug E (2005) Clinicopathological and epidemiological analysis of amyloidosis in Turkish patients. Nephrol Dial Transplant 20:1721-1725
2. Tunca M, Akar S, Onen F et al (2005) Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 84:1-11
3. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Eng J Med 314:1001-1005
4. Toto RD, Grundy SM, Vega GL (2000) Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome. Am J Nephrol 20:12-17
5. Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M (1987) Colchicine myopathy and neuropathy. N Engl J Med 316:1562-1568
6. Uçar M, Mjorndal T, dahlqvist R (2000) HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 22:441-457
7. Omar MA, Wilson JP, Cox TS (2001) Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 35:1096-1107
8. Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG (2004) Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 38:978-981
9. Lee AJ, Maddix DS (2001) Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 35:26-31
10. Shaukat A, Benekli M, Vladutiu GD, Slack JL, Wetzler M, Baer MR (2003) Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother 37:1032-1035
11. Tateishi T, Soucek P, Caraco Y et al (1998) Colchicine-induced myopathy with myotonia. Muscle Nerve 21:550-551